Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.
BACKGROUND
Alternative treatment strategies have become essential in overcoming the problem of drug-resistant Mycobacterium tuberculosis (Mtb). In this preliminary in vitro study, the anti-tuberculosis (anti-TB) activity of exogenous iron chelators (xenosiderophores) such as Exochelin-MS (Exo-MS) and Deferoxamine-B (DFO-B) was evaluated against ten multi-drug-resistant (MDR) and seven pyrazinamide-resistant (PZAR) Mtb isolates.


METHODS
Mycobacteria Growth Indicator Tube-Drug Susceptibility Test was used to assess the anti-TB effect of Exo-MS or DFO-B individually and their combinations with isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA).


RESULTS
For the MDR-Mtb isolates, Exo-MS alone inhibited two out of the five isolates tested. Whereas, DFO-B alone inhibited nine out of the ten MDR isolates tested. For PZA-resistant Mtb isolates, both Exo-MS and DFO-B individually inhibited five out of the seven isolates. The MIC of Exo-MS in combination with INH, RIF and PZA remained the same. The MIC of DFO-B decreased when tested in combination with INH, RIF and PZA.


CONCLUSIONS
Exo-MS and DFO-B were shown to have activity against drug-resistant Mtb isolates. Therefore, these xenosiderophores may be useful adjuncts to antibiotics in overcoming the problem of drug-resistant Mtb in clinical setting.
Department of Microbiology, Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, 400 002, India. karuna.gokarn@xaviers.edu.|Caius Research Laboratory, St. Xavier's College, Mumbai, 400 001, India. karuna.gokarn@xaviers.edu.
Karuna
http://orcid.org/0000-0002-4416-4328
K
Gokarn
Department of Microbiology, Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, 400 002, India.
Ramprasad B
RB
Pal
D000995:Antitubercular Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D024881:Drug Resistance, Bacterial; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000254:growth & development*; D012293:Rifampin / Q000494:pharmacology; D017262:Siderophores / Q000494:pharmacology*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000382:microbiology*
D000995:Antitubercular Agents; D017262:Siderophores; D007538:Isoniazid; D012293:Rifampin
Deferoxamine-B; Exochelin-MS; Mycobacteria growth indicator tube-drug sensitivity test; Tuberculosis; Xenosiderophores